What's New
Now Available: New Kinase Panel Rollout - 451 Kinase Assays!
The biggest in class kinase assay panel just got bigger & better!
KINOMEscan™, a leading provider of kinase inhibitor profiling services with the largest commercially available kinase assay panel, is excited to announce the expansion of its kinase assay panel with the release of nine new assays!
Now with 451 kinase assays, KINOMEscan continues to redefine the standard in selectivity profiling by providing high value kinase assays and screening solutions to drive kinase drug discovery.
New Kinase Assay Panel Highlights
- Novel activation-state specific autoinhibited assay pairs - identify and optimize activation-state sensitive inhibitors
- Expanded scanMODE assay panel - characterize inhibitor binding mode
- Expanded scanTK assay panel enables broader assessment
- Includes additions to CAMK, AGC, TK & Other kinase group assays
Circles represent kinase assays currently available in the KINOMEscan panel, blue circles represent new assays (Click to view larger image).
New Kinase Assays
What are autoinhibited assays?
KINOMEscan autoinhibited/non-autoinhibited PDGFR family RTK assay pairs represent the next generation of activation state-specific kinase assays that may be used to gain structural insights in the absence of cocrystal data and to collect in vitro data most predictive of inhibitor potency in cellular assays.
- Reports on the compatibility of an inhibitor’s binding mode with the autoinhibited conformation
- Collect activation state-specific biochemical PDGFR family RTK inhibition data necessary to predict & interpret potency in cellular assays
- Further differentiate inhibitors based on activation state-specific binding
- Explore & exploit inhibitor binding to diverse activation state-dependent kinase conformations
Learn more about KINOMEscan autoinhibited kinase assays >>